Xeris Pharmaceuticals’ $98.3 Million Initial Public Offering

Goodwin advised Xeris Pharmaceuticals on the deal

Xeris Pharmaceuticals (“XERS”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, closed its public offering of 6,555,000 shares of common stock at a price of $15.00 per share, before underwriting discounts, for gross proceeds of approximately $98.3 million.

Goodwin advised with a team includin Mitchell S. Bloom Stuart M. Cable and Joseph C. Theis, Jr. (Picture).

Involved fees earner: Mitchell Bloom – Goodwin Procter; Stuart Cable – Goodwin Procter; Joseph Theis Jr. – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Xeris Pharmaceuticals;


Author: Ambrogio Visconti